Implications of the Neuroprotective Effects of Lithium for the Treatment of Bipolar and Neurodegenerative Disorders

 

 Buy Article Permissions and Reprints

Bipolar disorder is increasingly recognized as an illness that may progress to impairment in neurocognitive functioning and cell loss in cortical and limbic brain regions. Glutamatergic damage and/or damage due to high glucocorticoid levels that inhibit adult neurogenesis are likely contributing mechanisms. Drug treatments with possible neuroprotective effects are becoming increasingly important both clinically and as research tools. Mood stabilizing drugs and lithium in particular may act to prevent neuronal damage and tissue loss that may occur in the brain of patients with bipolar disorders. Lithium has been shown to exert neuroprotective effects in vitro and to stimulate neurogenesis in the hippocampus. Animal studies have demonstrated pharmacological effects of lithium suggestive of its role in neuroprotection, which range from reducing excitotoxicity through increased glutamate uptake, to regulation of a number of signal transduction intermediates such as myo-inositol, protein kinase C, phosphotidylinositol-3 kinase (PI-3K)/protein kinase B (Akt), ras-mitogen-activated protein kinase (MAPK), glycogen synthase kinase (GSK)-3α and -3β and calcium. It remains to be established whether lithium treatment protects against possible cell damage in the same manner as it protects against recurrences of the illness. We propose to examine the effect of long-term lithium treatment on neurocognitive functioning of bipolar patients and the use of lithium in the treatment of chronic neuropsychiatric disorders.

References

• 1 Altshuler L L, Bartzokis G, Grieder T, Curran J, Jimenez T, Leight K, Wilkins J, Gerner R, Mintz J. An MRI study of temporal lobe structures in men with bipolar disorder or schizophrenia.  Biol Psychiatry. 2000;  48 147-162
  CrossrefPubMedGoogle Scholar
• 2 Bezchlibnyk Y, Young L T. The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression.  Can J Psychiatry. 2002;  47 135-148
  PubMedGoogle Scholar
• 3 Bown C D, Wang JF and Young L T. Attenuation of NMDA-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers.  Neuroscience. 2003;  117 949-955
  CrossrefPubMedGoogle Scholar
• 4 Carmichael J, Sugars K L, Bao Y P, Rubinsztein D C. Glykogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation.  J Biol Chem. 2002;  277 33 791-33 798
  PubMedGoogle Scholar
• 5 Chalecka-Franaszek E, Chuang D M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons.  Proc Natl Acad Sci USA. 1999;  96 8745-8750
  CrossrefPubMedGoogle Scholar
• 6 Chen B, Dowlatshahi D, MacQueen G M, Wang J, Young L T. Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication.  Biol Psychiatry. 2001;  50 260-265
  CrossrefPubMedGoogle Scholar
• 7 Chen G, Huang L D, Jiang Y M, Manji H K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.  J Neurochem. 1999;  72 1327-1330
  CrossrefPubMedGoogle Scholar
• 8 Chen G, Rajkowska G, Du F, Seraji-Bozorgzad Manji H K. Enhancement of hippocampal neurogenesis by lithium.  J Neurochem. 2000;  75 1729-1734
  CrossrefPubMedGoogle Scholar
• 9 Chen R W, Qin Z H, Ren M, Kanai H, Chalecka-Franaszek E, Leeds P, Chuang D M. Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection.  J Neurochem. 2003;  84 566-575
  CrossrefPubMedGoogle Scholar
• 10 Coyle J T, Duman R S. Finding the intracellular signaling pathways affected by mood disorder treatments.  Neuron. 2003;  38 157-160
  CrossrefPubMedGoogle Scholar
• 11 Cross D A, Alessi D R, Cohen P, Andjelkovich M, Hemmings B A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.  Nature. 1995;  378 785-789
  CrossrefPubMedGoogle Scholar
• 12 Datta S R, Brunet A, Greenberg M E. Cellular survival: a play in three Akts.  Genes Dev.. 1999;  13 2905-2927
  CrossrefPubMedGoogle Scholar
• 13 Davis G W, Schuster C M, Goodman C S. Genetic dissection of structural and functional components of synaptic plasticity. III. CREB is necessary for presynaptic functional plasticity.  Neuron. 1996;  17 669-679
  CrossrefPubMedGoogle Scholar
• 14 Deisseroth K, Bito H, Tsien R W. Signaling from synapse to nucleus: postsynaptic CREB phosphorylation during multiple forms of hippocampal synaptic plasticity.  Neuron. 1996;  16 89-101
  CrossrefPubMedGoogle Scholar
• 15 Denicoff K D, Ali S O, Mirsky A F, Smith-Jackson E E, Leverich G S, Duncan C C, Connell E G, Post R M. Relationship between prior course of illness and neuropsychological functioning in patients with bipolar disorder.  J Affect Disord. 1999;  56 67-73
  CrossrefPubMedGoogle Scholar
• 16 Deshauer D, Grof E, Alda M, Grof P. Patterns of DST positivity in remitted affective disorders.  Biol Psychiatry. 1999;  45 1023-1029
  CrossrefPubMedGoogle Scholar
• 17 Dixon J F, Hokin L E. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex.  Proc Natl Acad Sci USA. 1998;  95 8363-8367
  CrossrefPubMedGoogle Scholar
• 18 Dong G X, Singh D K, Dendle P, Prasad R M. Regional expression of Bcl-2 mRNA and mitochondrial cytochrome c release after experimental brain injury in the rat.  Brain Res. 2001;  903 45-52
  CrossrefPubMedGoogle Scholar
• 19 Drevets W C. Neuroimaging studies of mood disorders.  Biol Psychiatry. 2000;  488 13-828
  PubMedGoogle Scholar
• 20 Drevets W C, Ongur D, Price J L. Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders.  Mol Psychiatry. 1998;  3 220-6, 190 - 191
  CrossrefPubMedGoogle Scholar
• 21 Frame S, Cohen P, Biondi R M. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation.  Mol Cell. 2001;  7 1321-1327
  CrossrefPubMedGoogle Scholar
• 22 Ferrier I N, Stanton B R, Kelly T P, Scott J. Neuropsychological function in euthymic patients with bipolar disorder.  Br J Psychiatry. 1999;  175 246-251
  CrossrefPubMedGoogle Scholar
• 23 Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel R R, Czernik A, Giedke H, Muller-Oerlinghausen B, Osterheider M, Rudolf G AE, Sauer H, Tegeler J, Wetterling T. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study.  J Affect Disord. 1997;  43 151-161
  CrossrefPubMedGoogle Scholar
• 24 Grimes C A, Jope R S. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium.  J Neurochem. 2001;  78 1219-1232
  CrossrefPubMedGoogle Scholar
• 25 Grof P, Alda M, Grof E, Fox D, Cameron P. The challenge of predicting response to lithium stabilization. The importance of patient selection.  Br J Psychiatry. 1993;  163 ( 21) 16-19
  PubMedGoogle Scholar
• 26 Gyulai L, Bauer M, Bauer M S, García-España F, Cnaan A, Whybrow P C. Thyroid hypofunction in patients with rapid cycling bipolar disorder after lithium challenge.  Biol Psychiatry. 2003;  53 899-905
  CrossrefPubMedGoogle Scholar
• 27 Harris E C, Barraclough B. Excess mortality of mental disorder.  Br J Psychiatry. 1998;  173 11-53
  CrossrefPubMedGoogle Scholar
• 28 Hashimoto R, Fujimaki K, Jeong M R, Christ L, Chuang D M. Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity.  FEBS Lett. 2003;  538 145-148
  CrossrefPubMedGoogle Scholar
• 29 Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang D M. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation.  J Neurochem. 2002;  80 589-597
  CrossrefPubMedGoogle Scholar
• 30 Hashimoto R, Senatorov V, Kanai H, Leeds P, Chuang D -M. Lithium stimulates progenitor proliferation in cultured brain neurons.  Neuroscience. 2003;  117 55-61
  CrossrefPubMedGoogle Scholar
• 31 Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang D M. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity.  Neuropharmacology. 2002;  43 1173-1179
  CrossrefPubMedGoogle Scholar
• 32 Jope R S. Anti-bipolar therapy: mechanism of action of lithium.  Mol Psychiatry. 1999;  4 117-128
  CrossrefPubMedGoogle Scholar
• 33 Kane D J, Sarafian T A, Anton , Hahn H, Gralla E B, Valentine J S, Ord T, Bredesen D E. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species.  Science. 1993;  262 1274-1277
  PubMedGoogle Scholar
• 34 Kessing L V. Cognitive impairment in the euthymic phase of affective disorder.  Psychol Med. 1998;  38 1027-1038
  PubMedGoogle Scholar
• 35 Klein P S, Melton D A. A molecular mechanism for the effect of lithium on development.  Proc Natl Acad Sci USA. 1996;  93 8455-8459
  CrossrefPubMedGoogle Scholar
• 36 Kopnisky K L, Chalecka-Franaszek E, Gonzalez-Zulueta M, Chuang D M. Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities.  Neuroscience. 2003;  116 425-435
  CrossrefPubMedGoogle Scholar
• 37 Kowaltowski A J, Vercesi A E, Fiskum G. Bcl-2 prevents mitochondrial permeability transition and cytochrome c release via maintenance of reduced pyridine nucleotides.  Cell Death Differ. 2000;  7 903-910
  CrossrefPubMedGoogle Scholar
• 38 MacQueen G M, Grof P, Alda M, Marriott M, Young L T, Duffy A. Backward masking task performance in affected versus unaffected children of parents with lithium responsive bipolar disorder. Submitted. 
  Google Scholar
• 39 Manji H K, Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers.  Mol Psychiatry. 2002;  7 (Suppl 1) S46-56
  CrossrefPubMedGoogle Scholar
• 40 Manji H K, Moore G J, Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers.  Br J Psychiatry. 2001;  178 (Suppl 41) 107-119
  CrossrefPubMedGoogle Scholar
• 41 Manji H K, Moore G J, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders.  Mol Psychiatry. 2000;  5 578-593
  CrossrefPubMedGoogle Scholar
• 42 Manji H K, Quiroz J A, Sporn J, Payne J L, Denicoff K, A Gray N, Zarate CA J r, Charney D S. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.  Biol Psychiatry. 2003;  53 707-742
  CrossrefPubMedGoogle Scholar
• 43 Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder.  Lancet. 2002;  359 241-247
  CrossrefPubMedGoogle Scholar
• 44 Nemeth Z H, Deitch E A, Szabo C, Fekete Z, Hauser C J, Hasko G. Lithium induces NF-kappa B activation and interleukin-8 production in human intestinal epithelial cells.  J Biol Chem. 2002;  277 7713-7719
  CrossrefPubMedGoogle Scholar
• 45 Nonaka S, Chuang D M. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats.  Neuroreport. 1998;  9 2081-2084
  PubMedGoogle Scholar
• 46 Nonaka S, Hough C J, Chuang D. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx.  Proc Natl Acad Sci USA. 1998;  95 2642-2647
  CrossrefPubMedGoogle Scholar
• 47 Nonaka S, Katsube N, Chuang D M. Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine.  J Pharmacol Exp Ther. 1998;  286 39-47
  PubMedGoogle Scholar
• 48 Ongur D, Drevets W C, Price J L. Glial reduction in the subgenual prefrontal cortex in mood disorders.  Proc Natl Acad Sci USA. 1998;  95 13 290-13 295
  PubMedGoogle Scholar
• 49 Ozaki N, Chuang D M. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain.  J Neurochem. 1997;  69 2336-2344
  PubMedGoogle Scholar
• 50 Passmore M, Garnham J, Duffy A, MacDougall M, Munro A, Slaney C, Teehan A, Alda M. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine.  Bipol Disord. 2003;  5 110 - 114
  PubMedGoogle Scholar
• 51 Phiel C J, Klein P S. Molecular targets of lithium action.  Annu Rev Pharmacol Toxicol. 2001;  41 789-813
  CrossrefPubMedGoogle Scholar
• 52 Phiel C J, Wilson C A, Lee V M-Y, Klein P S. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides.  Nature. 2003;  423 435-439
  CrossrefPubMedGoogle Scholar
• 53 Pilcher H R. Drug research: the ups and downs of lithium.  Nature. 2003;  425 118-120
  CrossrefPubMedGoogle Scholar
• 54 Post R M, Uhde T W, Roy-Byrne P P, Joffe R T. Correlates of antimanic response to carbamazepine.  Psychiatr Res. 1987;  21 71-83
  CrossrefPubMedGoogle Scholar
• 55 Post R M, Weiss S RB. Neurobiological models of recurrence in mood disorder. In: Charney DS, Nestler EJ, Bunney BS, eds Neurobiology of Mental Illness. New York; Oxford University Press 1999: 365-384
  Google Scholar
• 56 Rajkowska G, Halaris A, Selemon L D. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder.  Biol Psychiatry. 2001;  49 741-752
  CrossrefPubMedGoogle Scholar
• 57 Ren M, Senatorov V V, Chen R -W, Chuang D -M. Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model.  Proc Natl Acad Sci USA. 2003;  100 6210-6215
  CrossrefPubMedGoogle Scholar
• 58 Ross E M. Signal sorting and amplification through G protein-coupled receptors.  Neuron. 1989;  3 141-152
  CrossrefPubMedGoogle Scholar
• 59 Rubinsztein J S, Michael A, Paykel E S, Sahakian B J. Cognitive impairment in bipolar affective disorder.  Psychol Med. 2000;  30 1025-1036
  CrossrefPubMedGoogle Scholar
• 60 Sapolsky R M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders.  Arch Gen Psychiatry. 2000;  57 925-935
  CrossrefPubMedGoogle Scholar
• 61 Silva A J, Kogan J H, Frankland P W, Kida S. CREB and memory.  Annu Rev Neurosci. 1998;  21 127-148
  CrossrefPubMedGoogle Scholar
• 62 Stambolic V, Ruel L, Woodgett J R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells.  Curr Biol. 1996;  6 1664-1668
  CrossrefPubMedGoogle Scholar
• 63 Strakowski S M, DelBello M P, Adler C, Cecil D M, Sax K W. Neuroimaging in bipolar disorder.  Bipol Disord. 2000;  2 148-164
  PubMedGoogle Scholar
• 64 Swann A C, Bowden C L, Morris D, Calabrese J R, Petty F, Small J, Dilsaver S C, Davis J M. Depression during mania. Treatment response to lithium or divalproex.  Arch Gen Psychiatry. 1997;  54 37-42
  CrossrefPubMedGoogle Scholar
• 65 Tham A, Engelbrektson K, Mathe A A, Johnson L, Olsson E, Aberg-Wistedt A. Impaired neuropsychological performance in euthymic with recurring mood disorders.  J Clin Psychiatry. 1997;  58 26-29
  PubMedGoogle Scholar
• 66 vanGorp W G, Altshuler L, Theberge D C, Wilkins J, Dixon W. Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence.  Arch Gen Psychiatry. 1998;  55 41-46
  PubMedGoogle Scholar
• 67 Walton M R, Dragunow I. Is CREB a key to neuronal survival?.  Trends Neurosci. 2000;  23 48-53
  CrossrefPubMedGoogle Scholar
• 68 Wang J F, Li P P, Warsh J J, Young L T. Signal transduction abnormalities in bipolar disorder. In: Young LT, Joffe RT, eds Bipolar disorder: biological models and their clinical application. New York; Marcel Dekker, Inc 1997: 41-79
  Google Scholar
• 69 Wei H, Qin Z -H, Senatorov V V, Wei W, Wang Y, Qian Y, Chuang D -M. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease.  Neuroscience. 2001;  106 603-612
  CrossrefPubMedGoogle Scholar
• 70 Young L T, Li P P, Kish S J, Warsh J J. Cerebral cortex beta-adrenoceptor binding in bipolar affective disorder.  J Affect Disord. 1994;  30 89-92
  CrossrefPubMedGoogle Scholar
• 71 Young L T, Joffe R T. Bipolar disorder: biological models and their clinical application. New York, NY; Marcel Dekker 1997
  Google Scholar
• 72 Yuan P, Chen G, Manji H K. Lithium activates the c-Jun NH2-terminal kinases in vitro and in the CNS in vivo.  J Neurochem. 1999;  73 2299-2309
  CrossrefPubMedGoogle Scholar
• 73 Yuan P X, Huang L D, Jiang Y M, Gutkind J S, Manji H K, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth.  J Biol Chem. 2001;  276 31 674-31 683
  PubMedGoogle Scholar

Michael Bauer, M.D., Ph. D.

Department of Psychiatry and Psychotherapy

Charité - University Medicine Berlin

Campus Charité-Mitte (CCM)

Schumannstr. 20/21

10117 Berlin

Germany

Phone: +49-30-450 51 70 70

Fax: +49-30-450-51 79 62

Email: michael.bauer@charite.de